← Leaderboards
Tufia C Haddad
Mayo Clinic Rochester
$809,100
Attributed
$1,618,200
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $335.4K · FY2017–21$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$1,618,200 · 1
By mechanism
R01$1,618,200 · 1
Top collaborators
- Antonio Bonaventura D'Assoro5 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Zhenkun Lou$18,569,951
- David Daniels$4,078,623
- Robert W Mutter$2,337,680
- Liewei Wang$11,536,599
- Justin L. Mott$4,114,486
Others in their field
Other Emerging Leaders on “Fulvestrant”
- Guangdi Wang · Zenopharm, Llc$2,293,076
- Lluis Morey · University Of Miami School Of Medicine$1,736,740
- Elizabeth Wellberg · University Of Colorado Denver$1,612,619
- Hong Zhao · Northwestern University$1,495,690
- Tracy E Crane · University Of Arizona$1,259,054
- Paul D Godfrin · Veramorph Llc$1,199,999
Research focus
FulvestrantGenetic TranscriptionBiological MarkersBloodBreast Cancer ModelBaseCd44 GeneCellsCharacteristicsClinical EfficacyClinically RelevantClonal ExpansionDependenceDiagnosisDoseDown-RegulationDoxycyclineDrug ResistanceEndocrineEstrogen Receptor AlphaEstrogen ReceptorsExperimental StudyFoundationsGrowth
Grant awards (5)
Targeting Aurora-A Kinase to Overcome Endocrine Resistance in ER+ Breast Cancer$315,236
R01 · FY2021 · CA
Targeting Aurora-A Kinase to Overcome Endocrine Resistance in ER+ Breast Cancer$324,060
R01 · FY2020 · CA
Targeting Aurora-A Kinase to Overcome Endocrine Resistance in ER+ Breast Cancer$324,569
R01 · FY2019 · CA
Targeting Aurora-A Kinase to Overcome Endocrine Resistance in ER+ Breast Cancer$318,937
R01 · FY2018 · CA
Targeting Aurora-A Kinase to Overcome Endocrine Resistance in ER+ Breast Cancer$335,398
R01 · FY2017 · CA